006140.Kq
The company designs, develops, and sells advanced medical equipment and technology, primarily generating revenue through the sale of diagnostic imaging systems and related services.
Business. The company designs, develops, and sells advanced medical equipment and technology, primarily generating revenue through the sale of diagnostic imaging systems and related services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company designs, develops, and sells advanced medical equipment and technology, primarily generating revenue through the sale of diagnostic imaging systems and related services.
The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 24,000,425,590, which is 41.3% of total assets. The liquidity FPT (free cash flow to total liabilities) is 9.3%, indicating a moderate ability to service liabilities from operating cash flows. The current ratio of 1.85 suggests the company can cover its short-term obligations with its current assets.
Profitability metrics show a return on equity (ROE) of 6.71% and a return on assets (ROA) of 4.72%, both below the industry median for Advanced Medical Equipment & Technology. The company's gross margin is 7.66%, and its operating margin is 6.14%, which are also below the industry median. These figures suggest the company is underperforming in terms of profitability relative to its peers.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The company's revenue is entirely derived from its core medical equipment business, with no material contributions from other product lines or services.
Looking ahead, the company is projected to grow revenue by 4.2% in the current fiscal year and 3.8% in the next fiscal year. This growth is driven by increased demand for diagnostic imaging systems and expansion into new markets. However, the company's capital expenditures are negative, indicating a reduction in investment in new facilities or equipment, which may limit long-term growth potential.
The company faces moderate liquidity risk due to a net cash position that is negative after subtracting total debt. The debt-to-equity ratio of 0.22 is low, suggesting minimal leverage risk. However, the company's dilution potential is low, with no significant dilutive events expected in the near term. The risk assessment indicates that the company is not currently at risk of issuing new shares to raise capital.
Recent events include the filing of the latest financial report, which disclosed a 12.3% increase in operating income compared to the previous year. The company also announced a new product launch in the diagnostic imaging segment, which is expected to drive future revenue growth. No major regulatory or legal issues were disclosed in the latest filings.
- The company has a strong liquidity position with a current ratio of 1.85 and significant cash reserves.
- Profitability metrics are below industry medians, indicating underperformance in terms of returns.
- Revenue is concentrated in a single business segment with no geographic diversification.
- The company is projected to grow revenue by 4.2% in the current fiscal year and 3.8% in the next fiscal year.
- The company faces moderate liquidity risk but has a low debt-to-equity ratio and minimal dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 006140.KQ Market data — financials · 2026-05-26
Ownership & reference
Leadership
- Myeong Wuk KimPresident, Chief Executive Officer, Director
Insider activity
Short positioning
Geographic breakdown
Intel & risk
4 tracked-field change(s) detected vs prior analysis; max severity: medium.
- Dilution risk— → lowlow
- Liquidity risk— → mediumlow
- Activity— → Healthcare Equipmentmedium
- Economic sector— → Healthcaremedium